A team of researchers at UCLA’s Jonsson Comprehensive Cancer Center, Cedars-Sinai Cancer, and Dana-Farber Cancer Institute have newly identified 34 genes that are associated with an increased risk for developing the earliest stages of ovarian cancer.
As the Galleri test is advancing toward becoming the first multi-cancer detection test to secure FDA approval, cancer care providers are coming up with strategies for using these tests responsibly.
